癌症基因治疗市场规模、份额、成长分析、按疗法、按适应症、按最终用户、按地区 - 行业预测，2024-2031

2022年癌症基因治疗市场规模估值为23.8亿美元，从2023年的28.6亿美元增长到2031年的126.3亿美元，预测期（2024-2031）的复合年增长率预计将保持在20.42%。

在基因研究和治疗策略进步的推动下，癌症基因治疗市场正在经历强劲成长。基因疗法透过针对疾病根本原因的精确基因干预，为治疗癌症提供了一条有前景的途径。推动这一增长的因素包括全球癌症发病率上升、对个人化治疗选择的需求不断增加以及越来越多地采用基因疗法作为可行的治疗方法。此外，持续的研究和开发计划、支持性法规结构以及与学术和製药部门的合作关係正在支持市场扩张。儘管面临治疗成本上升和监管复杂性等挑战，持续的技术创新和对癌症遗传学的深入了解预计将推动基因治疗的进一步进步，为市场带来光明的前景。

目录

介绍

• 这项研究的目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 成功的关键因素
• 竞争程度
• 监管分析
• 专利分析
• SWOT分析
• 赎回和监管场景
• 主要投资机会
• 管道分析
• 临床实验
• 市场吸引力指数
• 市场生态系统
• 案例研究

癌症基因治疗市场：依治疗分类

• 市场概况
• 基因诱导免疫疗法
• 溶瘤病毒疗法
• 基因转移

癌症基因治疗市场：依适应症分类

• 市场概况
• 乳癌
• 卵巢癌
• 肝癌
• 胰臟癌
• 肺癌
• 摄护腺癌
• 其他的

癌症基因治疗市场：依最终用户分类

• 市场概况
• 医院
• 诊断中心
• 研究机构
• 其他的

癌症基因治疗市场：按地区分類的规模

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 义大利
  • 英国
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Novartis AG（Switzerland）
• Biogen Inc.（US）
• Gilead Sciences, Inc.（US）
• Bristol-Myers Squibb（US）
• Rocket Pharmaceuticals（USA）
• Sarepta Therapeutics, Inc.（US）
• Vertex Pharmaceuticals（USA）
• Verve Therapeutics（USA）
• Voyager Therapeutics（USA）
• Johnson & Johnson（USA）
• AstraZeneca（UK）
• GlaxoSmithKline plc（UK）
• Celgene Corporation（USA）
• Bluebird bio Inc（USA）
• Amgen Inc.（USA）
• Alnylam Pharmaceuticals, Inc.（US）
• Merck & Co., Inc.（USA）
• Adaptimmune Therapeutics plc（UK）
• Euroscreen SA（Belgium）
• Vicore Pharma AB（Sweden）

Cancer Gene Therapy Market size was valued at USD 2.38 billion in 2022 and is poised to grow from USD 2.86 billion in 2023 to USD 12.63 billion by 2031, growing at a CAGR of 20.42% in the forecast period (2024-2031).

The market for cancer gene therapy is experiencing robust growth, propelled by advancements in genetic research and therapeutic strategies. Gene therapy offers a promising avenue for treating cancer through precise genetic interventions, targeting the underlying causes of the disease. Factors driving this growth include the rising global incidence of cancer, increasing demand for personalized treatment options, and expanding adoption of gene therapy as a viable treatment modality. Furthermore, ongoing research and development initiatives, supportive regulatory frameworks, and collaborations between academic and pharmaceutical sectors are bolstering market expansion. Despite challenges like high treatment costs and regulatory complexities, continuous innovation and deeper insights into cancer genetics are anticipated to drive further advancements in gene therapy, promising a brighter outlook for the market ahead.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cancer Gene Therapy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cancer Gene Therapy Market Segmental Analysis

The Cancer Gene Therapy market is segmented into segments i.e. by Therapy, Indication, End User and region. Based on Therapy, it is divided into Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer. Based on Indication, the market is segmented into Breast Cancer, Ovarian Cancer, Liver Cancer, Pancreatic Cancer, Lung Cancer, Prostate Cancer, and Others. Based on End Users the market is further segmented into Hospitals, Diagnostic centres, Research Institutes, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Cancer Gene Therapy Market

The cancer gene therapy market is driven by the growing global burden of cancer, which has spurred demand for more effective treatments. This trend stems from the escalating incidence of diverse cancer types, prompting the exploration and uptake of gene therapy strategies. Gene therapy for cancer holds promise in directly addressing specific genetic mutations underlying tumour development, thereby offering personalized and precise therapeutic solutions. This momentum is reinforced by continuous advancements in gene editing technologies and deeper insights into cancer genetics, facilitating the refinement and enhancement of therapeutic approaches. These factors collectively fuel the expansion and innovation within the field of cancer gene therapy.

Restraints in the Cancer Gene Therapy Market

A significant limitation in the global cancer gene therapy market stems from the intricate and challenging nature of gene therapy itself. This therapeutic approach necessitates the introduction of therapeutic genes into patient cells, a process fraught with technical complexities that can impact safety, effectiveness, and the sustainability of outcomes over time. Moreover, regulatory and ethical concerns, alongside the substantial expenses involved in research, development, and commercialization, further impede the widespread implementation of cancer gene therapy solutions. These combined factors present barriers to market expansion, underscoring the imperative for continued research and developmental efforts aimed at surmounting these obstacles and enhancing the viability of gene therapy as a treatment modality for cancer.

Market Trends of the Cancer Gene Therapy Market

A significant trend in the global cancer gene therapy market is the increasing emphasis on personalized and targeted treatments. This approach involves modifying cancer cells' genes to either inhibit their growth or stimulate the immune system's response against them. Advancements in genetic sequencing and molecular diagnostics enable researchers to pinpoint specific genetic abnormalities within individual patients' tumours. This knowledge is crucial as it facilitates the development of personalized gene therapies designed to target these specific genetic mutations or pathways. Tailoring treatments according to each patient's unique genetic profile holds promise for enhancing treatment efficacy and reducing adverse effects. Ultimately, personalized gene therapy represents a more precise and efficient strategy in the fight against cancer, potentially transforming treatment outcomes on an individualized basis.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Regulatory Analysis
• Patent Analysis
• SWOT Analysis
• Reimbursement & Regulatory Scenario
• Top Investment Pockets
• Pipeline Analysis
• Clinical Trail
• Market Attractiveness Index
• Market Ecosystem
• Case Study

Cancer Gene Therapy Market by Therapy

• Market Overview
• Gene Induced Immunotherapy
• Oncolytic Virotherapy
• Gene Transfer

Cancer Gene Therapy Market by Indication

• Market Overview
• Breast Cancer
• Ovarian Cancer
• Liver Cancer
• Pancreatic Cancer
• Lung Cancer
• Prostate Cancer
• Others

Cancer Gene Therapy Market by End User

• Market Overview
• Hospitals
• Diagnostic Centers
• Research Institutes
• Others

Cancer Gene Therapy Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • Italy
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rocket Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sarepta Therapeutics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vertex Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Verve Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Voyager Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bluebird bio Inc (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptimmune Therapeutics plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Euroscreen S.A. (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vicore Pharma AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments